Mark J. Tebbe

681 total citations
15 papers, 549 citations indexed

About

Mark J. Tebbe is a scholar working on Organic Chemistry, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Mark J. Tebbe has authored 15 papers receiving a total of 549 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Organic Chemistry, 5 papers in Molecular Biology and 3 papers in Infectious Diseases. Recurrent topics in Mark J. Tebbe's work include Viral Infections and Immunology Research (3 papers), Bioactive Compounds and Antitumor Agents (2 papers) and Catalytic Alkyne Reactions (2 papers). Mark J. Tebbe is often cited by papers focused on Viral Infections and Immunology Research (3 papers), Bioactive Compounds and Antitumor Agents (2 papers) and Catalytic Alkyne Reactions (2 papers). Mark J. Tebbe collaborates with scholars based in United States, Sweden and Germany. Mark J. Tebbe's co-authors include Paul A. Wender, Frantz Victor, Wayne A. Spitzer, Richard D. Connell, Emma R. McKinney, Paul Helquist, Björn Åkermark, Joseph Tang, Amy L. Cox and Michael J. Coghlan and has published in prestigious journals such as Diabetes, Journal of Medicinal Chemistry and Tetrahedron.

In The Last Decade

Mark J. Tebbe

15 papers receiving 511 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark J. Tebbe United States	11	318	192	96	58	47	15	549
Benjamin D. Stevens United States	15	112 0.4×	273 1.4×	130 1.4×	85 1.5×	65 1.4×	21	459
Dulce Garrido United States	11	183 0.6×	222 1.2×	58 0.6×	48 0.8×	51 1.1×	18	427
André Alker Switzerland	14	364 1.1×	243 1.3×	33 0.3×	6 0.1×	42 0.9×	31	695
Laïla El Kihel France	12	114 0.4×	161 0.8×	30 0.3×	17 0.3×	14 0.3×	22	337
Andy Vinter United Kingdom	5	105 0.3×	233 1.2×	46 0.5×	9 0.2×	30 0.6×	7	444
Frank Navas United States	14	209 0.7×	253 1.3×	10 0.1×	60 1.0×	112 2.4×	20	586
Ronald G. Sherrill United States	13	343 1.1×	224 1.2×	14 0.1×	12 0.2×	65 1.4×	19	629
John A. Wos United States	13	285 0.9×	249 1.3×	21 0.2×	12 0.2×	31 0.7×	34	565
Kang Man Lee South Korea	12	168 0.5×	246 1.3×	10 0.1×	8 0.1×	30 0.6×	31	429
Gui‐Bai Liang United States	15	332 1.0×	286 1.5×	66 0.7×	18 0.3×	57 1.2×	21	544

Countries citing papers authored by Mark J. Tebbe

Since Specialization

Citations

This map shows the geographic impact of Mark J. Tebbe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Tebbe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Tebbe more than expected).

Fields of papers citing papers by Mark J. Tebbe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Tebbe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Tebbe. The network helps show where Mark J. Tebbe may publish in the future.

Co-authorship network of co-authors of Mark J. Tebbe

This figure shows the co-authorship network connecting the top 25 collaborators of Mark J. Tebbe. A scholar is included among the top collaborators of Mark J. Tebbe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark J. Tebbe. Mark J. Tebbe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Sloop, Kyle W., Francis S. Willard, Martin Brenner, et al.. (2010). Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets. Diabetes. 59(12). 3099–3107. 121 indexed citations

Dodge, Jeffrey A., et al.. (2005). Structure activity studies of the serine-AIB dipeptide domain in 2,3-dihydroisothiazole based growth hormone secretagogues. Bioorganic & Medicinal Chemistry. 13(24). 6748–6762. 3 indexed citations

Chen, Shuhui, Frantz Victor, Robert B. Johnson, et al.. (2005). P1 and P1; Optimization of [3,4]-Bicycloproline P2 Incorporated Tetrapeptidyl α-Ketoamide Based HCV Protease Inhibitors. Letters in Drug Design & Discovery. 2(2). 118–123. 16 indexed citations

Victor, Frantz, Robert B. Johnson, John I. Glass, et al.. (2003). Discovery of a novel bicycloproline P2 bearing peptidyl α-ketoamide LY514962 as HCV protease inhibitor. Bioorganic & Medicinal Chemistry Letters. 14(1). 251–256. 38 indexed citations

Dios, Alfonso de, Lourdes Prieto, Almudena Rubio, et al.. (2002). 4-Substituted d-Glutamic Acid Analogues: The First Potent Inhibitors of Glutamate Racemase (MurI) Enzyme with Antibacterial Activity. Journal of Medicinal Chemistry. 45(20). 4559–4570. 54 indexed citations

Stratford, Robert E., Michael P. Clay, Beverly A. Heinz, et al.. (1999). Application of oral bioavailability surrogates in the design of orally active inhibitors of rhinovirus replication. Journal of Pharmaceutical Sciences. 88(8). 747–753. 5 indexed citations

Tebbe, Mark J., et al.. (1999). The effects of antirhino- and enteroviral vinylacetylene benzimidazoles on cytochrome P450 function and hepatic porphyrin levels in mice. Antiviral Research. 42(1). 25–33. 16 indexed citations

Tebbe, Mark J., et al.. (1997). Oral bioavailability screening of the antirhinoviral vinyl acetylene benzimidazoles. Antiviral Research. 34(2). A89–A89. 3 indexed citations

Tebbe, Mark J., et al.. (1997). Antirhino/Enteroviral Vinylacetylene Benzimidazoles: A Study of Their Activity and Oral Plasma Levels in Mice. Journal of Medicinal Chemistry. 40(24). 3937–3946. 113 indexed citations

10.

Tebbe, Mark J., et al.. (1997). Antirhinoviral vinyl acetylene benzimidazoles. Antiviral Research. 34(2). A75–A75. 3 indexed citations

11.

Wender, Paul A. & Mark J. Tebbe. (1994). The synthesis and chemistry of a simplified, functional analogue of neocarzinostatin chromophore: identification of an intramolecular 1,5-hydrogen atom. Tetrahedron. 50(5). 1419–1434. 23 indexed citations

12.

Connell, Richard D., Mark J. Tebbe, Anthony R. Gangloff, Paul Helquist, & Björn Åkermark. (1993). Rhodium-catalyzed heterocycloaddition route to 1,3-oxazoles as building blocks in natural products synthesis. Tetrahedron. 49(25). 5445–5459. 37 indexed citations

13.

Wender, Paul A. & Mark J. Tebbe. (1991). Nickel(0)-Catalyzed Intramolecular [4 + 4] Cycloadditions: 5. The Type II Reaction in the Synthesis of Bicyclo[5.3.1]undecadienes. Synthesis. 1991(12). 1089–1094. 60 indexed citations

14.

Connell, Richard D., Mark J. Tebbe, Paul Helquist, & Björn Åkermark. (1991). Direct preparation of 4-carboethoxy-1,3-oxazoles. Tetrahedron Letters. 32(1). 17–20. 32 indexed citations

15.

Wender, Paul A. & Mark J. Tebbe. (1991). Studies on DNA cleaving agents: synthesis and chemically induced cycloaromatization of a monocyclic neocarzinostatin chromophore analogue. Tetrahedron Letters. 32(37). 4863–4866. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact